All In Biotech

Drug Trial Radar · NCT01143389

Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

Evaluation of Two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus or Ectasia

Last checked: Nov 19, 2026Latest source record: Jun 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

510

Actual

Start

May 2010

Primary completion

May 30, 2017

Study completion Aug 30, 2017

Sponsor

Lead sponsor
Price Vision GroupIndustry
Sponsor type
Industry
First posted
Jun 14, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.

Conditions

  • Keratoconus
  • Post-Refractive Ectasia

Interventions

  • RiboflavinDrug

    Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.

  • UVX lightDevice

    UVX 365 nm wavelength light source is applied with continued application of riboflavin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Maximum Keratometry From Baseline to 6 Months After TreatmentTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Price Vision Group

    Indianapolis, Indiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.